clinical trial · NCT07140393
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.·phase2·recruiting·n = 120
Solid TumorHRS-4508+ CapecitabineHRS-4508+ TrastuzumabHRS-4508+ Trastuzumab+ PertuzumabHRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxelHRS-4508+ Trastuzumab + Nab-paclitaxelHRS-4508+ Trastuzumab+ CapecitabineTrastuzumab+ CapecitabineTrastuzumab+ Pertuzumab
brief summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.
started
Oct 28, 2025
primary completion
Oct 1, 2027
completion
Oct 1, 2028
last updated
Nov 19, 2026
official title
An Open, Multicenter Phase IB/II Clinical Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol